Stifel Nicolaus Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold

Article Stock Quotes (1) Comments (0)

Stifel Nicolaus upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Sell to Hold, with shares under heavy pressure after the company announced that hepatitis C drug IDX184 has been placed on partial clinical hold by the FDA due to a serious cardiac-related adverse event.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals are down 30 percent, but off the day's lows.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
• Stephens Upgrades IberiaBank (IBKC) to Overweight
• Deutsche Bank Upgrades T-Mobile US, (TMUS) to Buy

Create E-mail Alert Related Categories

Upgrades

Related Entities

Stifel Nicolaus

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?